Soy, isoflavone consumption not associated with endometrial cancer risk
the ONA take:
According to a new study published in the journal BJOG, an international journal obstetrics and gynecology, researchers from the National Cancer Center in Tokyo, Japan, have found that soy food/isoflavone consumption is not associated with endometrial cancer risk in Japanese women.
For the study, researchers sought to investigate whether a correlation exists between soy food/isoflavone consumption and endometrial cancer risk because consumption of soy food in Japan is very high while endometrial cancer incidence is very low.
Researchers conducted a prospective cohort study that included 49,121 Japanese women aged 45 to 74 years. Participants completed self-administered food frequency questionnaires that assessed intake of soy foods and isoflavones between 1995 and 1998, followed by a 5-year follow-up survey.
Results showed that during an average follow-up of 12.1 years, there were 112 cases of newly diagnosed endometrial cancer. The researchers found no association between soy food and isoflavone consumption and endometrial cancer risk.
Soy food/isoflavone consumption is not associated with endometrial cancer risk in Japanese women.
Sign Up for Free e-newsletters
- Avoiding the ED: Planned Strategies for Unplanned Urgent Cancer Care
- NP-Led Clinics Improved Phase 1 Oncology Study Operations, Outcomes
- Art as Palliative Care: Bedside Intervention Improves Pain, Anxiety, Mood in Hospitalized Cancer Patients
- Unprotected Sex After Chemotherapy
- Mindfulness Training May Improve End-of-Life Conversations in Advanced Cancer
- Study Suggests Greater Focus on the Needs of Family Caregivers of Patients With Cancer
- First Antibody-Based Treatment Regimen Approved for First-Line Treatment of Multiple Myeloma
- Increased Diabetes Risk Associated With Cancer Development
- Childhood Neuroblastoma Survivors at Risk for Psych Impairment
- Drug Classification of Trastuzumab
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|